** Mineralys Therapeutics' MLYS.O shares down 8.5% premarket to $26.40 after $150 mln equity offering

** Radnor, Pennsylvania-based MLYS early Weds says it sold ~5.66 mln shares at $26.50

** Offering price represents 8.1% discount to stock's last close

** BofA, Goldman Sachs and Evercore joint bookrunners

** Co intends to use net proceeds to partially fund $200 mln upfront payment for the repurchase of the royalty obligation under its license agreement with Tanabe Pharma Corporation relating to MLYS's blood pressure drug, lorundrostat

** MLYS also announced early Weds a $500 mln committed debt facility with funds managed by Pharmakon Advisors, LP

** With ~82.5 mln shares outstanding, MLYS has about $2.4 bln market cap

** Through Tues close, shares down ~21% YTD

** 9 of 10 analysts rate the stock "strong buy" or "buy", 1 "hold"; median PT $51.50, per LSEG data